Open AccessExtrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with Pegylated interferon alfa-2a and ribavirin
Author(s) -
Milotka Fabri,
Maja Ružić,
Dajana Lendak,
Tomislav Preveden,
Izabela Fabri,
Vedrana Petrić
Publication year - 2013
Publication title -
srpski arhiv za celokupno lekarstvo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 17
eISSN - 2406-0895
pISSN - 0370-8179
DOI - 10.2298/sarh1306320f
Subject(s) - medicine , ribavirin , gastroenterology , pegylated interferon , cirrhosis , hepatitis c , adverse effect , hepatitis c virus , rheumatoid factor , immunology , virus , rheumatoid arthritis
Thirty to 50% of patients with chronic hepatitis C (CHC) have one or more extrahepatic manifestations (EHMs) of hepatitis C virus (HCV) infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom